Skip to main content
SpringerLink
Log in

Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma

  • Chapter
  • First Online:
Ventilatory Disorders

Part of the book series: Advances in Experimental Medicine and Biology ((NR,volume 873))

Abstract

Lung cancer is still an oncology challenge. A 5-year survival reaches less than 20 % of patients. Apoptosis disturbances are a key step in cancer development. The evaluation of apoptosis markers has a great potential in lung cancer. The goal of our study was a comparative evaluation of apoptosis regulators: p53, Bcl-2, Bax, COX-2, and survivin in lung adenocarcinoma (AC) and squamous cell carcinoma (SCC). We also evaluated the relationship between apoptosis markers and clinicopathological parameters. Fifty six patients with non-small cell lung cancer (NSCLC) were included into the study (20 women and 36 men). AC was diagnosed in 30 and SCC in 26 cases. The evaluation of markers was performed using an immunohistochemical method on paraffin embedded tissue specimens. We used monoclonal antibodies for p53, bcl-2, and COX2-proteins (clone DO7, bcl-2/100/D5, and 4H12, respectively), Bax (B-9 clone) and survivin (clone 12C4). The results of immunostaining were viewed by light microscopy. We revealed significantly more frequent expression of Bax and survivin in lung AC than SCC (p < 0.01 and p < 0.019). Bcl-2 immunoreactivity was seen more often in AC without lymph node metastases than with metastases (p = 0.046). There was no correlation between the apoptosis markers and gender or the presence of vessel emboli. A greater variability in markers expression was seen in lung AC than SCC. There were significant differences in the Bax and survivin expression in the two major pathological types of NSCLC. We did not revealed any correlation between the markers and TNM characteristics, accept for Bcl-2 presence along with the lymph node involvement in the AC group.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki T, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T (1999) Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5:1001–1005

    CAS  PubMed  Google Scholar 

  • Cheng-Xiong X, Hua J, Myung-Haing C (2009) Apoptosis and apoptosis-based therapy in lung cancer. Anticancer Agents Med Chem 9:952–957

    Article  Google Scholar 

  • Cory S, Huang DC, Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22:8590–8607

    Article  CAS  PubMed  Google Scholar 

  • Daraselia N, Wang Y, Budoff A, Lituev A, Potapova O, Vansant G, Monforte J, Mazo I, Ossovskaya VS (2012) Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers. Am J Cancer Res 2:93–103

    PubMed Central  PubMed  Google Scholar 

  • Dohi T, Altieri DC (2005) Mitochondrial dynamics of survivin and ‘four dimensional’ control of tumor cell apoptosis. Cell Cycle 4:21–23

    Article  CAS  PubMed  Google Scholar 

  • Duarte ML, de Moraes E, Pontes E, Schluckebier L, de Moraes JL, Hainaut P, Ferreira CG (2009) Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines. Cancer Lett 279:57–64

    Article  CAS  PubMed  Google Scholar 

  • Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ (2008) Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy. Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26:848–855

    Article  CAS  PubMed  Google Scholar 

  • GLOBCAN (2012) Estimated cancer incidence, mortality and prevalence worldwide, WHO, IARC. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed on 10 May 2014

  • Greenhough A, Smartt HJ, Moore AE, Roberts HR, Willimas AC, Paraskeva C, Kaidi A (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumor microenvironment. Carcinogenesis 30:377–386

    Article  CAS  PubMed  Google Scholar 

  • Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM (2011) Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol 10:4320–4326

    Article  Google Scholar 

  • Han PH, Li XJ, Qin H, Yao J, DU N, Ren H (2009) Upregulation of survivin in non-small cell lung cancer and its clinicopathological correlation with p53 and Bcl-2. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 25:710–713

    CAS  PubMed  Google Scholar 

  • Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M (2003) Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancer. Cancer Sci 9:394–399

    Article  Google Scholar 

  • Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58:3761–3764

    CAS  PubMed  Google Scholar 

  • Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, Ochiai A (2000) Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 30:73–81

    Article  CAS  PubMed  Google Scholar 

  • Kim GY, Lim S-J, Kim YW (2011) Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas. Mod Pathol 24:1336–1347

    Article  CAS  PubMed  Google Scholar 

  • Lai RS, Wang JS, Hsu HK, Chang HC, Lin CH, Lin MC (2002) Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer. Jpn J Clin Oncol 32:393–397

    Article  PubMed  Google Scholar 

  • Milas I, Komaki R, Hachiya T, Bubb SR, Ro JY, Langford L, Sawaya R, Putnam JB, Allen P, Cox JD, McDonnell TJ, Brock W, Hong WK, Roth JA, Milas L (2003) Epidermal growth factor receptor, cyclooxygenase-2, and Bax expression in the primary non-small cell lung cancer and brain metastases. Clin Cancer Res 9:1070–1076

    CAS  PubMed  Google Scholar 

  • Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, Van Beek E Jr (2012) The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J Radiol 4:128–134

    Article  PubMed Central  PubMed  Google Scholar 

  • Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613–2622

    Article  CAS  PubMed  Google Scholar 

  • Molina MA, Simonetti S, Quiroga V, Viteri S, Campelo RG, Sanchezm J, Benlloch S, Aldeguer E, Taron M, Rosell R (2010) Survivin and CrkL expression in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations. J Clin Oncol 28(suppl):abstr e18063

    Google Scholar 

  • Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, Takahashi M, Fong KM, Shimokata K, Sekido Y (2004) p53 apoptotic pathway molecules are frequently and simultaneously altered in non small cell lung carcinoma. Cancer 15:1673–1682

    Article  Google Scholar 

  • Ohmura Y, Aoe M, Andou A, Shimizu N (2000) Telomerase activity and Bcl-2 expression in non-small cell lung cancer. Clin Cancer Res 6:2980–2987

    CAS  PubMed  Google Scholar 

  • Porebska I, Wyrodek E, Kosacka M, Adamiak J, Jankowska R, Harłozińska-Szmyrka A (2006) Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo 20:599–604

    CAS  PubMed  Google Scholar 

  • Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF (2003) Apoptosis and lung cancer: a review. J Cell Biochem 88:885–898

    Article  CAS  PubMed  Google Scholar 

  • Szutowicz E, Dziadziuszko R (2010) Quantitative immunohistochemistry in lung cancer: clinical perspective. Folia Histochem Cytobiol 48:7–11

    Article  PubMed  Google Scholar 

  • Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodrigez JA, Giaccone G (2004) Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 15:1654–1660

    Article  CAS  PubMed  Google Scholar 

  • Wistuba I (2012) Molecular pathogenesis of non-small cell lung carcinomas. J Lung Cancer 11:12–20

    Article  CAS  Google Scholar 

  • Yaren A, Oztop I, Kargi A, Ulukus C, Onen A, Sanli A, Binicier O, Yilmaz U, Alakavuklar M (2006) Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract 60:675–82

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was funded by the Wroclaw Medical University project no 1743.

Competing Interest

The authors declare that they have no competing interests in relation to this article.

Author information

Authors and Affiliations

  1. Department of Pulmonology and Lung Cancer, Silesian Piasts University of Medicine, 105 Grabiszyńska St., 53-439, Wroclaw, Poland

    I. Porębska, M. Kosacka & R. Jankowska

  2. Department of Clinical Immunology, Silesian Piasts University of Medicine, Wroclaw, Poland

    E. Sobańska & E. Wyrodek

Authors
  1. I. Porębska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kosacka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Sobańska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Wyrodek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Jankowska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Porębska .

Editor information

Editors and Affiliations

  1. Institute of Nursing, Public Higher Medical Professional Sch, Opole, Poland

    Mieczyslaw Pokorski

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Porębska, I., Kosacka, M., Sobańska, E., Wyrodek, E., Jankowska, R. (2015). Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma. In: Pokorski, M. (eds) Ventilatory Disorders. Advances in Experimental Medicine and Biology(), vol 873. Springer, Cham. https://doi.org/10.1007/5584_2015_121

Download citation

Publish with us

Policies and ethics

Search

Navigation